ECM loses Capsugel IPO but gets Sfr3bn Lonza rights issue
Another piece of next year’s equity capital markets issuance puzzle was turned over today, when Lonza, the Swiss pharmaceutical and chemical company, announced a Sfr3.3bn rights issue to pay for the acquisition of Capsugel from KKR.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: